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Abstract
NK cells are enriched in the liver, constituting around a third of intrahepatic lymphocytes. We have previously demonstrated
that they upregulate the death ligand TRAIL in patients with chronic hepatitis B virus infection (CHB), allowing them to kill
hepatocytes bearing TRAIL receptors. In this study we investigated whether, in addition to their pathogenic role, NK cells
have antiviral potential in CHB. We characterised NK cell subsets and effector function in 64 patients with CHB compared to
31 healthy controls. We found that, in contrast to their upregulated TRAIL expression and maintenance of cytolytic function,
NK cells had a markedly impaired capacity to produce IFN-c in CHB. This functional dichotomy of NK cells could be
recapitulated in vitro by exposure to the immunosuppressive cytokine IL-10, which was induced in patients with active CHB.
IL-10 selectively suppressed NK cell IFN-c production without altering cytotoxicity or death ligand expression. Potent
antiviral therapy reduced TRAIL-expressing CD56
bright NK cells, consistent with the reduction in liver inflammation it
induced; however, it was not able to normalise IL-10 levels or the capacity of NK cells to produce the antiviral cytokine IFN-c.
Blockade of IL-10 +/2 TGF-b restored the capacity of NK cells from both the periphery and liver of patients with CHB to
produce IFN-c, thereby enhancing their non-cytolytic antiviral capacity. In conclusion, NK cells may be driven to a state of
partial functional tolerance by the immunosuppressive cytokine environment in CHB. Their defective capacity to produce
the antiviral cytokine IFN-c persists in patients on antiviral therapy but can be corrected in vitro by IL-10+/2 TGF-b
blockade.
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Introduction
NK cells constitute a major cellular arm of the innate immune
system and, as such, have been viewed as most relevant in the
setting of the initial response to an acute infection. However, they
may also be appropriately or inappropriately activated to exert
effector function when persistent infection and its pathological
sequelae become established. Their role may be particularly
important in patients with CHB, in whom the virus-specific CD8
T cell arm of protection is markedly diminished and dysfunctional
[1,2].
NK cells are greatly enriched in the liver, the site of HBV
replication[3,4]. We have previously demonstrated an increase in
activated CD56
bright NK cells in the livers of patients undergoing
flares of eAg-negative CHB. This subset can be induced to express
TNF-related apoptosis-inducing ligand (TRAIL), which is able to
kill hepatocytes that have upregulated death-inducing TRAIL
receptors, thereby contributing to liver inflammation in CHB[4].
The CD56
bright subset can also be a potent source of cytokines
such as IFN-c[5,6], a key cytokine shaping adaptive immunity and
the delicate balance between protective and pathogenic responses.
IFN-c can clear HBV-infected hepatocytes through non-cytolytic
mechanisms[7,8]. NK cell-derived IFN-c could therefore consti-
tute a vital antiviral mechanism in the liver, where hepatocytes are
relatively resistant to the cytolytic mechanisms of perforin and
granzyme production[9].
The intensity and quality of NK cell effector function is
determined by the balance of activatory and inhibitory signals
through their array of receptors (NK-R), in addition to the
influences exerted by the cytokine microenvironment. The TRAIL
pathway of NK cell-mediated hepatocyte killing can be driven by
the cytokines IFN-a and IL-8, induced during flares of CHB[4].
Similarly, NK cells in HCV infection can be polarised towards
cytolysis and expression of TRAIL as a result of exposure to
endogenous[10] or therapeutic[11] IFN-a. Conversely, intrahe-
patic NK cell function can be down-regulated by the immuno-
suppressive cytokine IL-10 produced by Kupffer cells[12]. In
addition, a role for IL-17 in curtailing NK cell function was
recently demonstrated in disseminated vaccinia virus infection of
mice with pre-existing dermatitis[13]. In this study we have
PLoS Pathogens | www.plospathogens.org 1 December 2010 | Volume 6 | Issue 12 | e1001227investigated cytokine-driven modulation of IFN-c production by
NK cells in patients with CHB and explored the potential to
restore their non-cytolytic antiviral function.
Results
Expansion of the CD56
bright subset of NK cells in CHB
To explore NK cell effector potential in the setting of persis-
tent HBV infection, we first analysed the frequency of
CD56
bright(CD16
dim/
neg) and CD56
dim(CD16
pos) NK cell subsets
in 64 patients with CHB compared to 31 healthy age-matched
controls (Table 1). The proportion of circulating CD56
bright NK
cells was significantly increased in patients with CHB (represen-
tative FACS plots Fig1a, summary data Fig1b), with a tendency to
further increases in those with liver inflammation (Fig1b). There
was a trend for the percent of circulating NK cells to decrease in
CHB (Fig 1c) but the absolute number of circulating CD56
bright
NK cells was still significantly increased (p,0.05 data not
shown).
To determine whether there was a further enrichment of this
immunoregulatory CD56
bright NK cell subset at the site of viral
replication, we compared the proportions in intrahepatic and
circulating lymphocytes. In all eight patients with CHB from
whom paired samples were available, the percent of CD56
bright of
total NK cells was higher in the intrahepatic compared to
peripheral compartment (Fig1d,e). Since NK cells make up a
significantly greater proportion of intrahepatic than circulating
lymphocytes in these patients (Fig 1f), this corresponds to a
substantial enrichment of CD56
bright NK cells in the liver.
Impaired non-cytolytic antiviral potential of NK cells in
CHB
We have previously shown that the CD56
bright subset of NK
cells can mediate hepatocyte apoptosis through expression of the
death ligand TRAIL in flares of eAg-negative CHB[4]. In this
cohort of patients we confirmed an increase in TRAIL expression
(largely on the CD56
bright subset, Fig 2a representative plots) in
patients with either eAg+ or eAg- CHB who had evidence of liver
inflammation (Fig2a summary data).
The CD56
bright subset of NK cells can also be a potent source of
IFN-c[14], a cytokine that has direct non-cytolytic antiviral effects
on HBV replication [7,8] and can promote adaptive immune
responses[6]. Despite the enrichment of CD56
bright NK cells in
CHB, we found that they had an impaired capacity to produce
IFN-c (representative plots, Fig2b). There was a significant
reduction in production of IFN-c by NK cells from 46 patients
with CHB compared to 29 healthy controls (Fig2b). This reduction
was seen irrespective of disease activity (liver inflammation Fig2b,
viral load or eAg status, data not shown) or method of NK cell
stimulation (IL-12/IL-18 (Fig2b), IL-12/IL-15, K562 with IL-12/
IL-18 or PMA/ionomycin, data not shown). Both the CD56
bright
subset and the CD56
dim subset (that has recently been recognised
to also make a contribution to cytokine production[15]) showed
significantly impaired IFN-c production (FigS1a). Similarly,
CD56
bright and CD56
dim NK cells in CHB showed a trend to
produce less TNF-a, despite the strong stimulus required to
reliably elicit this cytokine (FigS1b). Simultaneous assessment of
IFN-c and TNF-a production showed a significant reduction in
dual producing NK cells in CHB (FigS1c).
To assess NK cell cytolytic potential, we determined their
capacity to degranulate as evidenced by CD107 expression
following stimulation with K562 target cells and cytokines. There
was no significant difference in NK cell degranulation potential in
33 patients with CHB compared to 21 controls (Fig2c). Differential
analysis by NK cell subset or by patient disease status did not show
any differences (data not shown). NK cells in CHB were therefore
biased towards cytolytic and death-ligand mediated effector
functions and defective IFN-c production.
To determine the potential of potent antiviral treatment to
correct this bias in NK cell effector function, we studied a group of
22 patients with HBV viraemia well-suppressed on a combination
of Lamivudine and Adefovir. Upon viral suppression and
normalisation of liver inflammatory markers, there was no
significant change in the percent of NK cells (FigS2a), but the
proportion of CD56
bright NK cells decreased to levels observed in
Author Summary
Hepatitis B virus (HBV) infection is responsible for more
than a million deaths annually as a result of the immune-
mediated chronic liver damage it induces. One of the key
immune players in the liver is the natural killer (NK) cell,
which we have recently found can cause liver damage in
HBV infection. Here we address the antiviral potential of
NK cells in the HBV-infected liver and demonstrate that
they have a specific impairment in their ability to produce
the cytokine IFN-c, which could limit their capacity to
control HBV. We find that the potent antiviral drugs
currently being used to treat HBV infection are unable to
fully reverse this NK cell functional defect. We define a role
for the immunosuppressive cytokine environment in HBV
in down-regulating NK cell antiviral function, which can be
restored by specific blockade of IL-10 and TGF-b. This work
therefore highlights a mechanism contributing to the
failure of immune control in chronic HBV infection, paving
the way to new therapeutic options.
Table 1. Characteristics of study population.
Healthy Controls
n=31
HBV Patients
High ALT
n=29
HBV Patients
Low ALT
n=35
Treatment Group
(Lamivudine
and Adefovir)
n=22
Age, years: median (range) 30 (18–52) 43.5 (23–65) 32 (23–65) 43 (18–70)
Sex (Female:male) 14:17 14:15 16:19 5:17
ALT IU/L: median (range) na 112 (57–604) 34 (10–47) 25 (18–70)
HBV DNA IU/mL: median (range) na 1,546,000 (1150–2.9610
8) 870 (100–3.3610
8) ,100
HBeAg+ na 18 3 6
na=not applicable.
doi:10.1371/journal.ppat.1001227.t001
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expression reduced to baseline levels (Fig2d). However NK cell
IFN-c production was only partially augmented upon antiviral
treatment (mainly CD56
dim subset, FigS2b) and remained
significantly lower than that in healthy controls (Fig2d).
IL-10 is induced in CHB and recapitulates the NK cell
defect in IFN-c production
Effector function of NK cells is tightly regulated by the cytokine
milieu and their production of IFN-c can be inhibited by
immunosuppressive cytokines such as IL-10[12,16] and IL-
17[13]. The levels of IL-17A were not elevated in sera from
patients with CHB compared to controls (Fig3a). In contrast,
circulating concentrations of IL-10 were significantly increased in
patients with active HBV disease (Fig3b,c by CBA, confirmed by
ELISA, data not shown), correlating with viral load (r=0.48,
p=0.002) and ALT (r=0.37, p=0.03). IL-10 levels showed a
trend to decrease on antiviral treatment but remained significantly
higher than in controls (Fig3c), consistent with the limited
restoration of NK cell IFN-c production in these patients.
To test whether IL-10 could induce the defect in NK cell IFN-c
production seen in CHB, we re-assessed NK cell effector function
with or without the addition of exogenous IL-10. IL-10
significantly suppressed NK-cell derived IFN-c (Fig3d), particu-
larly in those patients in whom it was not already substantially
reduced (Fig3e, and in healthy controls, data not shown). By
contrast, IL-10 had no effect on cytolytic ability or TRAIL
phenotype (Fig3f) and did not affect the percent of NK cells
(FigS3a). The ability of IFN-a to further induce NK cell TRAIL
expression in vitro[4] was also not abrogated by IL-10 (data not
shown). The effect of IL-10 was consistent but more modest on
purified NK cells (FigS3b), suggesting that some of its suppressive
activity on NK cells is mediated indirectly via other constituents
such as APCs. The contrasting effects of IL-10 on TRAIL and
IFN-c expression represented differential regulation of these
effector functions in the same NK cells rather than the emergence
of two distinct subsets. The small population of TRAIL-expressing
NK cells present in healthy donors were at least as able to produce
IFN-c as the rest of the NK cell population (FigS3c). The addition
of exogenous IL-10 suppressed IFN-c in NK cells regardless of
their TRAIL expression (FigS3c). In line with this, gating on the
expanded population of TRAIL-expressing NK cells found in
CHB demonstrated that their IFN-c-producing capacity was no
more reduced than that of the non-TRAIL-expressing fraction
(FigS3d).
Restoration of NK cell IFN-c production upon blockade of
immunosuppressive cytokines
Since IL-10 was induced in CHB and exogenous IL-10 was able
to mimic the selective suppression of NK cell effector function, we
next investigated the potential to restore NK cell IFN-c production
by IL-10 blockade. Addition of antiIL10/IL10-R blocking mAbs
restored the ability of both CD56
bright and CD56
dim NK cells from
patients with active CHB to produce IFN-c (mean 2.5 fold
increase, Fig4a,b,d). The majority of patients without biochemical
evidence of liver inflammation (and with low viral loads) did not
respond to this strategy (Fig4c,d), in line with their lower levels of
circulating IL-10 (Fig3b). A subset of those patients failing to
respond to IL-10 blockade did show recovery of NK cell IFN-c
production following blockade of both IL-10 and TGFb, another
immunosuppressive cytokine known to be able to inhibit NK cell
production (Fig4e,f).
To investigate whether the suppression of NK cell IFN-c was
maintained at the site of HBV replication, paired liver and blood
Figure 1. NK cell frequency and altered subset distribution in the periphery and intrahepatic compartment. (A) Representative density
plots gated on CD3- PBMC and co-stained for CD56 and CD16 to identify NK cells from a healthy control and a CHB patient. (B) Summary data of the
proportions of CD56
bright subset in the periphery of CHB patients with low ALT (n=35, ALT ,50IU/L, median 34) compared to high ALT (n=29,
median ALT 112) and healthy controls (n=31). (C) Frequency of circulating NK cells in CHB patients with low ALT and high ALT and healthy controls.
(D) Density plots of NK cells from peripheral blood and intrahepatic lymphocytes from a representative CHB patient. (E) Paired cumulative results of
peripheral and intrahepatic CD56
bright NK cells frequencies from 8 patients with CHB. (F) NK cell frequency in peripheral blood and intrahepatic
compartment from 8 patients with CHB with paired samples. The non-parametric Mann-Whitney U test was used to compare data between groups
and the Wilcoxon signed rank test was used between paired variables. *p,0.05 or ** p,0.01 designates values that differ significantly between
groups. Ctr = healthy controls.
doi:10.1371/journal.ppat.1001227.g001
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CD56
bright NK cell IFN-c production showed a trend to be even
lower in the liver than the periphery of patients with CHB
(FigS4a). Levels of intrahepatic NK cell IFN-c production did not
significantly correlate with levels of ALT (FigS4b), viral load or
liver histology in this small sample of patients, only one of whom
had histological evidence of significant liver inflammation (Table
2). Due to limited cell numbers, individual cytokine blockade could
not be performed but dual IL-10/TGFbRII blockade reconstitut-
ed the proportion of NK cells able to produce IFN-c (%positive,
Fig5a) and increased their level of IFN-c production (MFI, Fig5b).
The fold increase in the capacity of CD56
bright NK cells to secrete
IFN-c upon IL-10/TGFb blockade was greater in the liver than
the periphery (Fig5a,b).
Discussion
Accumulating evidence points to a contribution of NK cells in
the battle to control persistent intracellular pathogens[6,17,18].
Although NK cells have been considered part of the innate
immune response, recent data have suggested that they can possess
properties previously ascribed to the adaptive arm, including the
Figure 2. Skewed NK cell effector function in CHB is only partially corrected during therapy. (Panels A–C) Representative density plots
from a healthy control and HBV patients with low ALT (ALT ,50 IU/L, median 33) and raised ALT (ALT.50 IU/L, median 112) and summary data for
TRAIL expression, IFN-c production and CD107 expression. (D) Summary bar charts of CD56
bright proportions, NK cell TRAIL expression and NK cell
IFN-c production from healthy, CHB and patients on antiviral therapy. Results are expressed as mean 6 SEM. Rx = treated patients. *p,0.05,
**p,0.01, ***p,0.001 by Mann-Whitney test.
doi:10.1371/journal.ppat.1001227.g002
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we show that NK cells can develop selective defects in antiviral
function in the setting of chronic infection and inflammation,
reminiscent of the hierarchical loss of effector function manifested
by exhausted T cells[22].
Just as T cell defects have been attributed to excessive antigenic
stimulation, functional impairment of NK cells has been ascribed
to excessive stimulatory signals through the activating receptor
NKG2D, resulting in its down-modulation[19,20]. This is a
plausible mechanism in CHB since data from transgenic mice
suggest that HBV can upregulate the intrahepatic expression of
NKG2D ligands[23]. However, a recent study and our unpub-
lished data do not support this mechanism, showing no down-
regulation of NKG2D or consistent changes in other NK cell
receptors that could account for the NK cell impairment seen in
CHB[24]. Instead, our data suggest that the selective NK cell
functional defects seen in this infection may be attributable to the
immunosuppressive cytokine milieu.
Our analysis of NK cell effector potential in a large cohort of
patients with CHB revealed preservation of cytolytic capacity and
an increase in TRAIL-bearing CD56
bright NK cells. Despite this
increase in the subset of NK cells that are usually the most potent
source of cytokines[14], there was a decrease in the overall NK cell
capacity to produce IFN-c. Such divergence of effector function is
in line with the recent finding that cytokines are trafficked and
secreted via completely different pathways to cytotoxic granules in
NK cells[25]. Consistent with these distinct trafficking pathways,
separate signalling pathways have been shown to control the
release of cytokines and cytotoxic granules in NK cells[26,27].
Unique molecular switches are starting to be identified that couple
Figure 3. IL-10 is elevated in CHB and suppresses NK cell IFN-c production. (A) Levels of cytokines IL-17A and (B) IL-10 determined using
Cytometric Bead Arrays flex sets using sera from 13 healthy controls, 14 low ALT (median ALT 35, all eAg-) and 21 high ALT patients (median ALT 115,
13eAg-). (C) Cumulative IL-10 results including therapy group (n=13, median ALT 25). (D) Representative density plots of the effect of exogenous IL-
10 on IFN-c production by NK cells from a CHB patient and (E) paired cumulative results from 19 CHB patients. (F) Summary bar charts of the effect of
exogenous IL-10 on the expression of TRAIL and CD107 in 5 CHB patients. Results are paired and expressed as mean 6 SEM. Stimulus = IL12+IL18.
Significance determined by the Mann-Whitney test for comparison between groups and the Wilcoxon signed rank test for paired data, *p,0.05,
**p,0.01, ***p,0.001.
doi:10.1371/journal.ppat.1001227.g003
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than cytotoxic functions[28,29]. It is therefore conceivable that a
pathway specific to NK cell cytokine production is dysregulated in
patients with CHB.
The immunosuppressive cytokine IL-10 has been shown to
specifically impair NK cell IFN-c production[30], in contrast with
IL-17 and excessive NKG2D signalling, both of which result in
down-modulation of all NK cell effector functions[13,20]. The
liver is an immunotolerant organ, predisposed to the production of
immunosuppressive cytokines; down-regulation of intrahepatic
NK cell IFN-c production has been linked to the local release of
IL-10 by Kupffer cells[12,31]. We found that exposure of NK cells
to IL-10 in vitro was able to recapitulate the selective reduction in
IFN-c production noted in patients with CHB. Furthermore, its
blockade was able to restore the capacity of NK cells from patients
with active HBV infection to produce IFN-c. IL-10 was not able to
inhibit cytotoxic degranulation and could not overcome the
capacity of IFN-a to induce TRAIL, in line with the maintenance
of these pathogenic functions of NK cells in CHB. IL-10 was
consistently modestly elevated in the serum of patients with CHB,
but would be expected to be at higher concentrations at the site of
infection in the liver and in close proximity to the cells from which
it is released. NK cells themselves can produce IL-10[14,32] to
allow auto-suppression, but in the HBV-infected liver there are a
number of other candidate cellular sources and there is likely to be
a complex regulatory network involved in maintaining its
production, as recently described in HIV infection[33].
We recently reported a transient induction of IL-10 in early
acute HBV infection that was temporally associated with a
transient suppression of the capacity of NK cells to produce IFN-c,
Figure 4. IL-10 blockade alone or in combination with TGFbRII blocking restores NK cell IFN-c production. (A) Representative density
plot from a CHB patient of peripheral NK cell IFN-c production in the presence of anti-IL-10 and anti-IL10 receptor blocking mAb. (B) Paired summary
data from CHB patients with either active disease (High ALT median 104, n=13) or (C) inactive disease (Low ALT median 33, n=9). (D) Fold change in
IFN-c produced by total NK cells following IL-10 blockade in both groups of patients. (E, F) Representative density dot plots from a CHB patient and
summary bar chart of paired results from 11 patients (n=11 median ALT 42) of NK cell IFN-c production following IL-10 blockade alone or in
combination with anti-TGFbRII blocking antibodies. Stimulus = IL12+IL18. Significance determined by the Mann-Whitney test for comparison
between groups and the Wilcoxon signed rank test for paired data, *p,0.05, **p,0.01.
doi:10.1371/journal.ppat.1001227.g004
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antigens[16]. In our cohort of patients with CHB it was difficult to
distinguish the influence of viraemia or liver inflammation, since
both were increased in patients with elevated levels of IL-10.
Future study of a group of patients with high viral load but normal
ALT (immunotolerant phase) could help to dissect the role of these
factors. The fact that NK cell IFN-c production and IL-10 levels
were not significantly normalised by potent antiviral therapy
suggests that the continued secretion of high levels of HBV
proteins in these patients may play a role. In patients with low level
CHB without evidence of liver inflammation, IL-10 was not
elevated and its blockade alone could not rescue NK function,
which instead required additional TGF-b blockade. TGF-b is
another immunosuppressive cytokine that characterises the
tolerising liver environment and has been shown to be increased
in CHB[34]. TGF-b has been shown to be an alternative key
regulator of the capacity of human NK cells to produce IFN-c,
suppressing IFN-c and T-bet via Smad2/3/4[35].
Figure 5. Blockade of IL10/TGF enhances intrahepatic NK cell IFN-c production. (A) Representative density plots and (B) histograms for
total intrahepatic NK cell and CD56
bright subset IFN-c production upon blockade with anti-lL-10, anti-IL10 receptor and anti-TGFbRII blocking
antibodies. Paired summary bar charts of fold change increase in the percentage and mean fluorescence intensity (MFI) of NK total and CD56
bright
IFN-c+ cells in the periphery and intrahepatic compartment of 7 CHB (median ALT 56). Results are expressed as mean 6 SEM. Stimulus = IL12+IL18.
*p,0.05 by Wilcoxon signed rank test.
doi:10.1371/journal.ppat.1001227.g005
Table 2. Patient characteristics with available liver biopsy specimens.
Patients
n=8
Age
Median 35.5
Range 24–66
Sex
M:F
6:2 HBeAg+ 2/6
HBV DNA (IU/mL)
Median 66,879
Range 646–1.2610
6
ALT (IU/L)
Median 56
Range 15–113
Necro-
inflammatory
score
Modified ISHAK
Stage Fibrosis
Pt1 25 F Pos 113,757 113 2/18 1/6
Pt2 32 M Pos 310,000 63 4/18 3/6
Pt3 49 M Neg 700,000 15 na 1/6
Pt4 40 F Neg 20,000 26 3/18 1/6
Pt5 24 M Neg 947 86 2/18 1/6
Pt6 66 M Neg 646 56 3/18 1/6
Pt7 39 M Neg 6500 26 3/18 1/6
Pt8 27 M Neg 1.2610
6 56 3/18 1/6
na=not available.
doi:10.1371/journal.ppat.1001227.t002
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important feedback mechanism to limit exuberant immune
responses and tissue immunopathology in a vital organ like the
liver. However, in the context of chronic infections, elevated levels
may attenuate immune responses sufficiently to contribute to the
failure of resolution of infection. A role for IL-10 in persistent viral
infection has been highlighted recently by studies showing that
blockade of the IL-10 receptor is associated with resolution of
LCMV infection[36,37]. Genetic studies have also highlighted the
importance of IL-10 in the antiviral response to HBV; polymor-
phisms of the IL-10 promoter resulting in elevated IL-10
production are associated with viral persistence, increased disease
severity and progression[38,39].
Our data suggest that immunosupressive cytokines may polarise
NK cells in CHB, having no effect on their expression of death
ligands and cytolytic granules but inhibiting IFN-c production.
NK cells expressing death ligands like TRAIL would only be able
to have a direct antiviral effect at the expense of liver damage. The
decline in liver inflammation seen on antiviral treatment is
compatible with the reduction in TRAIL-expressing CD56
bright
NK cells that we noted in this setting. However, potent antiviral
therapy was unable to significantly restore the capacity of NK
cells to produce IFN-c, which would therefore retain an impair-
ed capacity for non-cytolytic clearance of HBV from hepatocytes
and boosting of adaptive immune responses. Our findings raise
the possibility of immunotherapeutic targeting of IL-10 and
TGF-b in CHB, with the caveat that these cytokines govern a
critical balance between impeding pathogen clearance and re-
straining immunopathology.
Materials and Methods
Ethics statement
Clinical assessment and blood sampling were performed during
routine hepatitis clinics, with written informed consent and local
ethical board approval of the Royal Free Hospital, the Royal
London Hospital and Camden Primary Care Ethics Review
Board.
Patients and healthy subjects
All patients were anti-Hepatitis C- and anti-Human Immuno-
deficiency Virus-antibody negative and treatment naı ¨ve with the
exception of a sub-group of 22 patients suppressed on a
combination of Lamivudine and Adefovir. Patient characteristics
are included in Table 1. Paired peripheral blood and liver biopsy
specimens (surplus to diagnostic requirements) were obtained from
8 CHB-infected patients (Table 2).
Isolation and storage of PBMC and Intrahepatic
lymphocyte isolation
Peripheral blood mononuclear cells (PBMC) were isolated by
gradient centrifugation on Ficoll-Hypaque and frozen or imme-
diately studied as described later. Sera were collected and frozen
for later use. Intrahepatic lymphocytes were isolated as previously
described[4].
Extracellular staining and flow cytometric analysis
For phenotypic analysis, PBMC isolated from HBV patients
and healthy donors were stained with fluorochrome-conjugated
antibodies to CD3-Cy5.5/PerCP, CD56-FITC, CD16-APC, and
TRAIL-PE or isotype matched controls (BD Biosciences, Cowley,
U.K.). In selected experiments TRAIL expression was determined
following overnight incubation with 50 ng/mL of rhIL-10
(eBioscience). PBMC were acquired on a FACS Calibur flow
cytometer (Becton Dickinson) and analysed using Flowjo analysis
software (Treestar).
Cytokine production by intracellular staining
As previously described[16], PBMC were incubated with
50 ng/mL of rhIL-12 (Miltenyi) and rhIL-18 (R&D Systems,
Abingdon, U.K.) for 21 hours at 37uC. 1mM monensin (Sigma-
Aldrich, Gillingham, U.K.) was added for the final 3 hours. Cells
were fixed and permeabilised followed by intracellular staining for
IFN-c-PE (R&D systems). Where indicated the same experiments
were performed in the presence of rhIL-10 (50ng/mL), or blocking
antibodies to anti-IL10 (5 mg/mL) (eBioscience) and anti-IL-10R
(10 mg/mL) alone or in combination with antiTGFbRII (10 mg/
mL) (BD Biosciences). NK IFN-c production was determined by
subtracting baseline IFN-c production from that observed after
cytokine or antibody treatment. NK cells from PBMC of a
randomly selected group of patients were isolated (.96% purity
and viability) (Miltenyi Biotec, Germany, NK isolation kit) to
assess the effect of exogenous IL-10 on IFN-c production.
For TNF-a production, PBMC were stimulated with phorbol
myristate acetate (PMA) (3 ng/mL) and ionomycin (100 ng/mL)
(Sigma) for 3 hours; 1mM monensin (Sigma-Aldrich, Gillingham,
U.K.) was added for the final 2 hours. Cells were then stained with
the same antibody combination used for phenotyping prior to
permealisation and intracellular staining for TNF-a. In selected
experiments NK cell TNF-a and IFN-c co-expression was assessed
following PMA/I stimulation.
CD107 degranulation assay
As previously described[16], PBMC were incubated with K562
cells (5:1 E:T ratio) for 3 hours at 37uC following overnight
stimulation with a combination of rhIL-12/rhIL-18 or medium
alone in the presence or absence of rh-IL10. CD107a-PE antibody
(BD Biosciences, Cowley, U.K.) was added at the time of
stimulation with target cells and 1mM monensin was added
during the last two hours of the incubation prior to staining and
acquisition.
Determination of serum cytokine concentrations by
Cytometric Bead Array (CBA)
CBA flex-sets were used for the determination of IL-10, IL-17
(BD Biosciences, Cowley, U.K) according to manufacturers’
protocols for serum samples.
Statistical analysis
Statistical significance was performed between paired samples
using the Wilcoxon signed rank test and between HBV patients
and healthy controls using the Mann-Whitney U test. Correlations
between variables were evaluated with the Spearman rank
correlation test. P,0.05 was considered to be significant for all
tests.
Supporting Information
Figure S1 Summary bar charts comparing production of (A)
IFN-c and (B) TNF-a from NK total and NK cell subsets in
healthy controls and CHB patients. (C) 10 healthy controls and 12
CHB patients were evaluated for the co-production of TNF-a and
IFN-c following stimulation with PMA/I. Summary bar charts
show the percentage of total NK cells that are single positive for
IFN-c, TNF-a and double positive for IFN-c/TNF-a.* P ,.05,
**P,.01, ***P,.001 by Mann-Whitney test.
Found at: doi:10.1371/journal.ppat.1001227.s001 (0.48 MB EPS)
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PLoS Pathogens | www.plospathogens.org 8 December 2010 | Volume 6 | Issue 12 | e1001227Figure S2 (A) Frequencies of circulating NK cells and (B)
summary bar chart comparing production of IFN-c from NK total
and NK cell subsets in healthy controls (n=29), CHB patients
(n=46) and HBV patients on antiviral treatment (n=20). *P,.05,
**P,.01, ***P,.001 by Mann-Whitney test.
Found at: doi:10.1371/journal.ppat.1001227.s002 (0.46 MB EPS)
Figure S3 (A) Representative FACS plots showing the effect of
exogenous IL10 on NK cells frequencies (boxed CD56+CD32)
(B) NK cells from 4 eAg- CHB patients (median ALT 50, median
VL 2300) were negatively purified (.96% purities) and stimulated
with IL-12/IL-18 in the presence or absence of exogenous IL-10.
The effect of IL-10 is shown for the CD56
bright subset (**P,.01
significance determined by paired t test). (C) Representative density plots
and histograms from a healthy control and (D) a CHB patient
showing NK cell IFN-c production, gated on the
CD56+CD32TRAIL- and CD56+CD32TRAIL+ populations,
following stimulation with IL12/IL18 +/2 IL-10. NK cell IFN-c
production is expressed as MFI.
Found at: doi:10.1371/journal.ppat.1001227.s003 (0.92 MB EPS)
Figure S4 (A) Production of IFN-c by circulating and intrahe-
patic NK cells and NK cell subsets from 8 CHB patients with
available liver samples. Paired summary bar charts expressed as
mean 6 SEM. (B) Lack of significant correlation between
intrahepatic NK cell IFN-c production and ALT. Spearman
statistical test was performed (r=-0.39, p=0.32).
Found at: doi:10.1371/journal.ppat.1001227.s004 (0.46 MB EPS)
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